Patents by Inventor Marc A. Gavin

Marc A. Gavin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and Compositions for Treating Cancer
    Publication number: 20240307537
    Abstract: This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).
    Type: Application
    Filed: August 17, 2023
    Publication date: September 19, 2024
    Inventors: Michael Cicirelli, Neil S. Cutshall, Gregory A. Demopulos, George A. Gaitanaris, Marc A. Gavin, Alexander Gragerov, Thomas L. Little, Rene Onrust
  • METHODS AND COMPOSITIONS FOR TREATING CANCER
    Publication number: 20230285556
    Abstract: Compounds, compositions, and methods for generating T cells with altered phenotype are disclosed. The phenotype-altered T cells have increased persistence, prolonged survival, and increased antitumor activity and are useful for treatment of cancers.
    Type: Application
    Filed: September 12, 2022
    Publication date: September 14, 2023
    Inventors: George A. Gaitanaris, Marc A. Gavin, Robert H. Lemus, Caglar Cekic, Mohammed Oukka, Trupti Vardam-Kaur
  • METHODS OF TREATING GRAFT VERSUS HOST DISEASE USING IL-2 MUTEINS
    Publication number: 20230139534
    Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
    Type: Application
    Filed: December 20, 2022
    Publication date: May 4, 2023
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Li LI
  • Method of promoting regulatory T-cell proliferation
    Patent number: 11560415
    Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: January 24, 2023
    Assignee: AMGEN INC.
    Inventors: Marc A. Gavin, Li Li
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 10829535
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: November 10, 2020
    Assignee: Amgen Inc.
    Inventors: Marc A. Gavin, Gunasekaran Kannan, Li Li, Joshua T. Pearson, Margaret Karow
  • Methods and Compositions for Treating Cancer
    Publication number: 20200345725
    Abstract: This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).
    Type: Application
    Filed: January 10, 2020
    Publication date: November 5, 2020
    Inventors: Michael Cicirelli, Neil S. Cutshall, Gregory A. Demopulos, George A. Gaitanaris, Marc A. Gavin, Alexander Gragerov, Thomas L. Little, Rene Onrust
  • Methods and compositions relating to anti-IL-21 receptor antibodies
    Patent number: 10184002
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: January 22, 2019
    Assignee: AMGEN INC.
    Inventors: Marc A. Gavin, Ai Ching Lim
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20180319859
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: February 21, 2018
    Publication date: November 8, 2018
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 9932380
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: April 3, 2018
    Assignee: Amgen Inc.
    Inventors: Marc A. Gavin, Gunasekaran Kannan, Li Li, Joshua T. Pearson, Margaret Karow
  • METHODS OF TREATING GRAFT VERSUS HOST DISEASE USING IL-2 MUTEINS
    Publication number: 20170313753
    Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
    Type: Application
    Filed: July 13, 2017
    Publication date: November 2, 2017
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Li LI
  • Method of treating graft versus host disease using IL-2 muteins
    Patent number: 9732134
    Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: August 15, 2017
    Assignee: Amgen Inc.
    Inventors: Marc A Gavin, Li Li
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20170137485
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: January 17, 2017
    Publication date: May 18, 2017
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 9580486
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 28, 2017
    Assignee: Amgen Inc.
    Inventors: Marc A. Gavin, Gunasekaran Kannan, Li Li, Joshua T. Pearson, Margaret Karow
  • METHODS AND COMPOSITIONS RELATING TO ANTI-IL-21 RECEPTOR ANTIBODIES
    Publication number: 20160176971
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
    Type: Application
    Filed: March 1, 2016
    Publication date: June 23, 2016
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Ai Ching LIM
  • Compositions relating to anti-IL-21 receptor antibodies
    Patent number: 9309318
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 12, 2016
    Assignee: Amgen, Inc.
    Inventors: Marc A. Gavin, Ai Ching Lim
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20140343252
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: November 20, 2014
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20140286898
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Gunasekaran KANNAN, Li LI, Joshua T. PEARSON, Margaret KAROW
  • METHODS AND COMPOSITIONS RELATING TO ANTI-IL-21 RECEPTOR ANTIBODIES
    Publication number: 20140105900
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 17, 2014
    Applicant: AMGEN INC.
    Inventors: Marc A. GAVIN, Ai Ching LIM
  • COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES
    Publication number: 20110274650
    Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
    Type: Application
    Filed: January 20, 2010
    Publication date: November 10, 2011
    Applicant: AMGEN INC.
    Inventors: Marc A. Gavin, Li Li